Global burden, risk factors, and temporal trends of ureteral cancer: a comprehensive analysis of cancer registries.

BACKGROUND: Ureteral cancer is a rare cancer. This study aimed to provide an up-to-date and comprehensive analysis on the global trends of ureteral cancer incidence and its association with lifestyle and metabolic risk factors. METHODS: The incidence of ureteral cancer was estimated from the Cancer Incidence in Five Continents Plus and Global Cancer Observatory databases. We analyzed the (1) global incidence of ureteral cancer by region, country, sex, and age group by age-standardized rates (ASR); (2) associated risk factors on a population level by univariable linear regression with logarithm transformation; and (3) incidence trend of ureteral cancer by sex and age group in different countries by Average Annual Percentage Change (AAPC). RESULTS: The global age-standardized rate of ureteral cancer incidence in 2022 was 22.3 per 10,000,000 people. Regions with higher human development index (HDI), such as Europe, Northern America, and East Asia, were found to have a higher incidence of ureteral cancer. Higher HDI and gross domestic product (GDP) and a higher prevalence of smoking, alcohol drinking, physical inactivity, unhealthy dietary, obesity, hypertension, diabetes, and lipid disorder were associated with higher incidence of ureteral cancer. An overall increasing trend of ureteral cancer incidence was observed for the past decade, especially among the female population. CONCLUSIONS: Although ureteral cancer was relatively rare, the number of cases reported was rising over the world. The rising trends among females were more evident compared with the other subgroups, especially in European countries. Further studies could be conducted to examine the reasons behind these epidemiological changes and confirm the relationship with the risk factors identified.

Recent trends in incidence, mortality, survival, and treatment of upper tract urothelial carcinoma.

BACKGROUND: To examine the recent trends in incidence, incidence-based mortality, survival, and treatment of upper tract urothelial carcinoma (UTUC) from 2004 to 2019 and investigate whether patients would benefit from adjuvant chemotherapy. METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, we identified 18,422 patients diagnosed with UTUC from 2004 to 2019. Joinpoint regression analyses were used to test the trends in annual percentage change (APC) for statistical significance. RESULTS: From 2004 to 2019, the incidence of all UTUC decreased from 1.46 to 1.27 per 100,000 person-years [APC: -1.11, P<0.001]. In subgroup analysis, the incidence decreased for localized, regional and stage I-II, but increased for distant. Over the study period, changes in trend for 5-year cancer specific survival [APC: -0.21, P=0.676] and 5-year overall survival [APC: 0.18, P=0.751] of all UTUC were not significant. The 5-year cancer specific survival and 5-year overall survival for regional and stage III cancer improved significantly from 2004 to 2014. Since 2004, rates of treatment with nephroureterectomy combined with chemotherapy increased significantly [APC: 7.38, P<0.001], while rates of treatment with nephroureterectomy alone decreased significantly [APC: -1.89, P<0.001]. CONCLUSION: The overall incidence of UTUC is reduced, with a significant reduction in the incidence of early stage UTUC but an increase in the incidence of late stage UTUC. No significant change in IBM was observed over the study period. No significant improvement in survival for early stage UTUC. Significant improvements in regional and stage III survival were observed with active adjuvant chemotherapy. There is also an excess of combination therapy. LEVEL OF EVIDENCE: 8.

Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey.

OBJECTIVE: To report national data on diagnostics and treatment of upper tract urothelial carcinoma (UTUC) from the Swedish National Registry of Urinary Bladder Cancer (SNRUBC). PATIENTS AND METHODS: Data from 2015 to 2021 were retrieved, and descriptive analyses were performed regarding incidence, diagnostic modalities, preoperative tumor staging, quality indicators for treatment including the use of standardized care pathways (SCP) and multidisciplinary tumor boards (MDTB). Time trends were explored for the study period. RESULTS: Registrations included 1,213 patients with renal pelvic cancer and 911 patients with ureteric cancer with a median age of 74 (interquartile range [IQR] 70-77) and 75 (IQR 71-78) years, respectively. Incidence rates of UTUC were stable, as were proportions of curative treatment intent. Median number of days from referral to treatment was 76 (IQR 57-99) and 90 (IQR 72-118) days, respectively, for tumors of the renal pelvis and ureter, which remained unchanged after introduction of SCP in 2016. Noticeable trends included stable use of kidney-sparing surgery and increased use of MDTB. For radical nephroureterectomy (RNU), robot-assisted technique usage increased even for non-organ-confined tumors (cT3-4) and in one out of three patients undergoing RNU a bladder cuff excision was not registered. CONCLUSIONS: The population-based SNRUBC with high coverage contributes to the knowledge about UTUC with granular and generalizable data. The present study reveals a high proportion of patients not subjected to curatively intended treatment and suggests unmet needs to shorten lead times to treatment and use of bladder cuff excision when performing radical surgery for UTUC in Sweden.

Radical nephrectomy and nephroureterectomy in patients over 80 years old

PURPOSE: The aim of this study was to discover if elderly patients exhibit comparable outcomes and survival benefits to those achieved in younger patients. MATERIALS AND METHODS: We assessed 35 patients over 80 years old treated by radical nephrectomy or nephroureterectomy for malignant and inflammatory conditions within the previous 4 years. A multivariate analysis regarding survival and recovery was conducted and included various preoperative parameters. The subjective opinion of patients or patient's relatives (in cases where the patient had past away) was estimated by answering the following questions: (a) are you satisfied with your decision to undergo the operation? (b) would you undergo it once more if needed? (c) would you advise it to a patient your age? RESULTS: The median age was 83.5 years. Radical nephrectomy with a flank approach was performed in 65.7 percent of cases and nephroureterectomy with a transabdominal approach in 34.3 percent of cases. The median recovery was 13 weeks. During a median follow-up of 31 months (range 12 to 53), 80 percent of patients were disease free. The remaining 20 percent passed away demonstrating a median survival of 25 months (range 13-38). Eighty-eight percent of patients were satisfied with their decision to undergo the operation, 91.4 percent would undergo it once more if needed and 91.4 percent would advise it to a patient their age. CONCLUSIONS: Radical nephrectomy and nephroureterectomy are safe and effective in well-selected patients over 80 years old. Elderly patients exhibit comparable preoperative outcomes and survival benefits to those achieved in younger patients. Various preoperative clinical variables that effect the survival of patients but not their recovery could be identified.

Epidemiología del cáncer de pelvis renal en pacientes del Hospital Nacional Essalud "Guillermo Almenara Irigoyen" Lima - Perú: estudio retrospectivo y descriptivo 1999-2005 / Epidemiology of the renal pelvis cancer in patients of the Guillermo Almenara Irigoyen General Hospital Lima - Perú: retrospective and descriptive study 1999-2005

El cáncer de vía urinaria alta (pelvis renal y/o uréter) es una neoplasia rara. Generalmente es del tipo células de transición. El objetivo de este trabajo es conocer los aspectos epidemiológicos, clínicos y de manejo de los pacientes institucionales con esta patología que han consultado en el Hospital Nacional “Guillermo Almenara Irigoyen”en Lima - Perú. Se revisaron retrospectivamente los ingresos al Servicio de Urología entre los años 1999 al 2005. Se recuperaron 26 ingresos con este diagnóstico. Se analizan sexo, edad, antecedentes clínicos, síntomas, exámenes de laboratorio, tipo histológico, tratamientos, complicaciones y seguimiento. Las edades fluctuaron entre los 47 y 82 años (promedio de 64,8 años). El 53,8 por ciento fueron mujeres. El tabaquismo lamentablemente no se consigna en los ingresos. La hematuria fue el principal síntoma. El 100 por ciento presentaba hematuria en el examen de orina. El 19,2 por ciento estaban con metástasis al momento del diagnóstico. Casi todos los pacientes tuvieron manejo quirúrgico clásico de forma convencional o laparoscópica. El 100 por ciento tenían carcinoma de células transicionales. Las complicaciones perioperatorias fueron mínimas. No se registra mortalidad operatoria. Esta patología es un cáncer poco frecuente, que debe sospecharse ante toda hematuria, que es el principal motivo de consulta. Idealmente el diagnóstico debe ser precoz. Su manejo debe ser esencialmente quirúrgico.

Introduction: Upper urinary tract tumors are infrequent. However when present, they are usually related to transitional cell carcinoma. The purpose of this study was to analyze epidemiologic, clinic and therapeutic aspects of this disease in the Hospital Nacional “Guillermo Almenara Irigoyen” in Lima - Perú. Material and Methods: A Retrospective review of all our admissions between 1999 and 2005 was performed. A total of 26 patients were admitted with this diagnosis. Gender, age, clinical findings, pathology, treatment and follow-up are analyzed.Results: Mean age was 64,8 years (47-82 years), 53,8 percent were women. Tobacco consumption did not appear in the admission data. The chief complaint was hematuria and 100 percent had microscopic hematuria in the lab tests. Almost all the patients underwent surgery (mainly nephroureterectomy with partial cistectomy). All cases had transitional cell cancer. There were minimal complications and no surgical mortality. Conclusions: Carcinoma of the upper urinary tract is infrequent, must be suspected in the event of hematuria. Ideally diagnosis should be preoperative with histological confirmation. Most of the cases are transitional cell cancer, and management must be essentially surgical.